ABOUT US

Our Mission

Genegobio Inc. is a healthcare investment firm specializes in funding and supporting businesses in the life sciences sectors. We provide capital to medical startups, biotech companies, and medtech innovators, often focusing on areas like precision medicine, medical devices, or digital health solutions. Beyond financing, we offer strategic guidance, industry connections, technology supports, supply chain solutions and expertise to help portfolio companies grow and succeed. Our goal is to drive innovation in healthcare while generating strong financial returns for investors.

As a cross-border pharmaceutical enablement, Genegobio Inc. bridges scientific innovation with global commercialization success. We deliver end-to-end solutions spanning technology licensing, supply chain intelligence, and regulatory acceleration, empowering clients across 15+ countries to transform complex challenges into market leadership.

Core Expertise:

IP Commercialization | Strategic licensing models unlocking value from patents to profits
Smart Supply Chains | Data-driven supplier optimization reducing costs by 18-25% annually
Regulatory Mastery | 100% approval rate for U.S./Latin American/ Middle East/China/CIS/EAEU submissions

Genegobio Inc. is committed to providing pharmaceutical companies with access to top-tier expertise and resources, ensuring the highest quality of care for patients worldwide.

U.S. and E.U. Markets

For the North American market, We support Washington D.C.’s initiative to bolster local manufacturing through expert technology transfer services. Our offerings include advanced formulations, biosimilars and active pharmaceutical ingredients (APIs), enabling clients to enhance domestic production with efficiency and compliance.

Latin American Market

In the Latin American market, we collaborates closely with leading pharmaceutical companies to develop complex and challenging medicines, delivering tailored solutions that meet rigorous industry standards. Our expertise extends to innovative product licensing, enabling regional partners to bring cutting-edge therapies to market with efficiency and precision.

CIS & Middle East Market

In the CIS and Middle East markets, we partner closely with local regulatory authorities to expedite market entry, achieving orphan drug approvals in as little as 3 months, medicins for 12 months and medical device approvals within 6 months. By collaborating directly with regional wholesalers, we streamline distribution channels, enabling swift and cost-effective delivery of pharmaceutical products to hospitals and pharmacies without intermediaries.